ArticleBMC infectious diseases2017
The impact of influenza on the health related quality of life in China: an EQ-5D survey.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal.PharmacoEconomics - open · 2026Pooled it
- Raising the patient's voice in influenza research and care: a systematic review of patient-reported outcomes.BMC infectious diseases · 2026Pooled it
- The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults.Advances in therapy · 2024Pooled it
- The Impact of Influenza on Health-Related Quality of Life, Work Productivity, and Activity Impairment Among Symptomatic US Patients with Influenza.Infectious diseases and therapy · 2026Article
- Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China.Infectious medicine · 2026Article
- Influenza Vaccine Uptake in the Elderly: Biopsychosocial Vulnerabilities and Effectiveness of a Community-Health Worker Administered Preventive Program.Journal of community health · 2026Article
- Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study.Human vaccines & immunotherapeutics · 2025Article
- Cost-effectiveness and public health impact of influenza vaccination strategies for Chinese patients with rheumatoid arthritis.Human vaccines & immunotherapeutics · 2025Article
- Determining health-related quality of life among children with malaria in Kenya: does the choice of EQ-5D value set matter?Health and quality of life outcomes · 2025Article
- Community-acquired pneumonia in hospitalized adults: long-term morbidities and their risk factors.BMC infectious diseases · 2025Article
- Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza Vaccination.China CDC weekly · 2024Article
- Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Miyun District of Beijing, China: An EQ-5D survey.Vaccine: X · 2023Article
- Cost-effectiveness of seasonal influenza vaccination of children in China: a modeling analysis.Infectious diseases of poverty · 2023Article
- Ambient temperature and air pollution associations with suicide and homicide mortality in California: A statewide case-crossover study.The Science of the total environment · 2023Article
- Assessing the patient experience of respiratory syncytial virus infection: development of a patient-reported outcome measure.Health and quality of life outcomes · 2023Review
- Article
- Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China.Frontiers in microbiology · 2023Article
- Quality of Life in Post-COVID-19 Patients after Hospitalization.Healthcare (Basel, Switzerland) · 2022Article
- Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.British journal of clinical pharmacology · 2021Article
- Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study.BMC health services research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundInfluenza causes considerable morbidity and mortality in China, but its impact on the health-related quality of life (HRQoL) has not been previously measured.
methodsWe conducted a retrospective telephone survey to assess the impact of influenza on the HRQoL among outpatients and inpatients using the EuroQoL EQ-5D-3 L instrument. Participants were individuals with laboratory-confirmed influenza infection registered by the National Influenza-like-illness Surveillance Network in 2013.
resultsWe interviewed 839 of 11,098 eligible influenza patients. After excluding those who were unable to complete the HRQoL for the registered influenza episode, 778 patients were included in the analysis. Both outpatients (n = 529) and inpatients (n = 249) most commonly reported problems with pain/discomfort (71.8% of outpatients and 71.9% of inpatients) and anxiety/depression (62.0% of outpatients and 75.1% of inpatients). For individual influenza outpatients, the mean health utility was 0.6142 (SD 0.2006), and the average quality adjusted life days (QALD) loss was 1.62 (SD 1.84) days. The HRQoL of influenza inpatients was worse (mean health utility 0.5851, SD 0.2197; mean QALD loss 3.51 days, SD 4.25) than that of outpatients (p < 0.05). The presence of underlying medical conditions lowered the HRQoL for both outpatients and inpatients (p < 0.05).
conclusionsInfluenza illness had a substantial impact on HRQoL. QALD loss due to an acute influenza episode in younger children was comparable to that due to enterovirus A71-associated hand, foot and mouth disease. Our findings are key inputs into disease burden estimates and cost-effectiveness evaluations of influenza-related interventions in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.